Cardiovascular prevention in subjects with impaired fasting glucose or impaired glucose tolerance

Massimo Volpe, Claudio Borghi, Paolo Cavallo Perin, Massimo Chiariello, Enzo Manzato, Roberto Miccoli, Maria Grazia Modena, Gabriele Riccardi, Giorgio Sesti, Antonio Tiengo, Bruno Trimarco, Diego Vanuzzo, Paolo Verdecchia, Augusto Zaninelli, Stefano Del Prato

Research output: Contribution to journalArticle

Abstract

Cardiovascular diseases still represent the leading cause of mortality and hospitalization, particularly in Western countries. As a consequence of the marked changes observed on the demographic characteristics of the general population, the improved survival rate after an acute cardiovascular event, and the progressive rise of costs (mostly due to technological and pharmacological innovations), the estimated burden of cardiovascular diseases will soon become insurmountable for national healthcare systems. In this view, an integrated approach aimed at improving strategies for cardiovascular disease prevention and, thus, limiting the negative outcomes, would probably be successful. Such an approach may not only achieve long-term benefits, but even significant advantages in the short to medium term, mostly in asymptomatic high-risk individuals. Indeed, this latter population of asymptomatic high-risk individuals would mostly benefit from extensive application and improvement of strategies for cardiovascular disease prevention with a favourable cost-benefit ratio.The Italian Society for Cardiovascular Disease Prevention Societ Italiana per la Prevenzione Cardiovascolare (SIPREC) has recognized this strategic aim, focusing a vast majority of its institutional action on the effort for providing educational supports and consensus documents, which represent an overview of the scientific knowledge and personal clinical expertise by national and international key opinion leaders. Expert committees periodically generate 'state-of-the-art' documents on specific scientific topics with relevant socioeconomic implications and large clinical impact. The present article is dedicated to healthcare professionals, and is based on the available evidence, and provides useful information on diagnostic algorithms and therapeutic options. In 2006, the SIPREC Scientific Committee promoted a consensus document on the metabolic syndrome,1 which is still widely used, frequently cited and updated, from which originated a broad educational programme throughout the Italian territory. This programme has certainly contributed to improving knowledge of a widespread clinical condition, such as the metabolic syndrome, which SIPREC interpreted not only as a theoretical pathophysiological concept or a nosographic entity, but rather as a real clinical tool for identifying and 'intercepting' those asymptomatic individuals at risk of cardiovascular events, before the estimated level of risk becomes high.This new article may be viewed in the same strategic line. The relationship between abnormalities in blood glucose metabolism (or dysglycaemia) and cardiovascular complications represents another important and relatively early target for cardiovascular disease prevention. SIPREC Scientific Committee identified even in this clinical setting an excellent group of scientific experts, in order to collect a ultidisciplinary 'task force'. This group has been asked to explain in a short, simple and effective fashion the epidemiological impact and the pathophysiological nature of the problem, its clinical features, potential diagnostic algorithms and therapeutic options, and its influence on the clinical practice of both specialist physicians and general practitioners.The work of this Task Force, which is reported in this article, is primarily a baseline for discussing novel future strategies for cardiovascular prevention. Also, this article is aimed at highlighting the importance of an emerging marker of cardiovascular risk, which is little recognized and often undervalued. Dysglycaemia, in turn, has a clinical significance, which is at least, in part, comparable with that of type 2 diabetes mellitus, both in terms of epidemiological prevalence and of long-term cardiovascular prognosis.

Original languageEnglish
Pages (from-to)73-102
Number of pages30
JournalHigh Blood Pressure and Cardiovascular Prevention
Volume17
Issue number2
DOIs
Publication statusPublished - 2010

Fingerprint

Glucose Intolerance
Fasting
Cardiovascular Diseases
Glucose
Advisory Committees
Inventions
Delivery of Health Care
Population Characteristics
General Practitioners
Type 2 Diabetes Mellitus
Cost-Benefit Analysis
Blood Glucose
Consensus
Hospitalization
Survival Rate
Demography
Pharmacology
Physicians
Costs and Cost Analysis
Mortality

Keywords

  • abnormal glucose regulation
  • cardiovascular prevention
  • diabetes mellitus
  • hypertension
  • impaired glucose tolerance
  • insulin resistance
  • metabolic syndrome

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Internal Medicine

Cite this

Cardiovascular prevention in subjects with impaired fasting glucose or impaired glucose tolerance. / Volpe, Massimo; Borghi, Claudio; Cavallo Perin, Paolo; Chiariello, Massimo; Manzato, Enzo; Miccoli, Roberto; Modena, Maria Grazia; Riccardi, Gabriele; Sesti, Giorgio; Tiengo, Antonio; Trimarco, Bruno; Vanuzzo, Diego; Verdecchia, Paolo; Zaninelli, Augusto; Del Prato, Stefano.

In: High Blood Pressure and Cardiovascular Prevention, Vol. 17, No. 2, 2010, p. 73-102.

Research output: Contribution to journalArticle

Volpe, M, Borghi, C, Cavallo Perin, P, Chiariello, M, Manzato, E, Miccoli, R, Modena, MG, Riccardi, G, Sesti, G, Tiengo, A, Trimarco, B, Vanuzzo, D, Verdecchia, P, Zaninelli, A & Del Prato, S 2010, 'Cardiovascular prevention in subjects with impaired fasting glucose or impaired glucose tolerance', High Blood Pressure and Cardiovascular Prevention, vol. 17, no. 2, pp. 73-102. https://doi.org/10.2165/11311830-000000000-00000
Volpe, Massimo ; Borghi, Claudio ; Cavallo Perin, Paolo ; Chiariello, Massimo ; Manzato, Enzo ; Miccoli, Roberto ; Modena, Maria Grazia ; Riccardi, Gabriele ; Sesti, Giorgio ; Tiengo, Antonio ; Trimarco, Bruno ; Vanuzzo, Diego ; Verdecchia, Paolo ; Zaninelli, Augusto ; Del Prato, Stefano. / Cardiovascular prevention in subjects with impaired fasting glucose or impaired glucose tolerance. In: High Blood Pressure and Cardiovascular Prevention. 2010 ; Vol. 17, No. 2. pp. 73-102.
@article{0f2e8c3a7af44123807138916554b8e7,
title = "Cardiovascular prevention in subjects with impaired fasting glucose or impaired glucose tolerance",
abstract = "Cardiovascular diseases still represent the leading cause of mortality and hospitalization, particularly in Western countries. As a consequence of the marked changes observed on the demographic characteristics of the general population, the improved survival rate after an acute cardiovascular event, and the progressive rise of costs (mostly due to technological and pharmacological innovations), the estimated burden of cardiovascular diseases will soon become insurmountable for national healthcare systems. In this view, an integrated approach aimed at improving strategies for cardiovascular disease prevention and, thus, limiting the negative outcomes, would probably be successful. Such an approach may not only achieve long-term benefits, but even significant advantages in the short to medium term, mostly in asymptomatic high-risk individuals. Indeed, this latter population of asymptomatic high-risk individuals would mostly benefit from extensive application and improvement of strategies for cardiovascular disease prevention with a favourable cost-benefit ratio.The Italian Society for Cardiovascular Disease Prevention Societ Italiana per la Prevenzione Cardiovascolare (SIPREC) has recognized this strategic aim, focusing a vast majority of its institutional action on the effort for providing educational supports and consensus documents, which represent an overview of the scientific knowledge and personal clinical expertise by national and international key opinion leaders. Expert committees periodically generate 'state-of-the-art' documents on specific scientific topics with relevant socioeconomic implications and large clinical impact. The present article is dedicated to healthcare professionals, and is based on the available evidence, and provides useful information on diagnostic algorithms and therapeutic options. In 2006, the SIPREC Scientific Committee promoted a consensus document on the metabolic syndrome,1 which is still widely used, frequently cited and updated, from which originated a broad educational programme throughout the Italian territory. This programme has certainly contributed to improving knowledge of a widespread clinical condition, such as the metabolic syndrome, which SIPREC interpreted not only as a theoretical pathophysiological concept or a nosographic entity, but rather as a real clinical tool for identifying and 'intercepting' those asymptomatic individuals at risk of cardiovascular events, before the estimated level of risk becomes high.This new article may be viewed in the same strategic line. The relationship between abnormalities in blood glucose metabolism (or dysglycaemia) and cardiovascular complications represents another important and relatively early target for cardiovascular disease prevention. SIPREC Scientific Committee identified even in this clinical setting an excellent group of scientific experts, in order to collect a ultidisciplinary 'task force'. This group has been asked to explain in a short, simple and effective fashion the epidemiological impact and the pathophysiological nature of the problem, its clinical features, potential diagnostic algorithms and therapeutic options, and its influence on the clinical practice of both specialist physicians and general practitioners.The work of this Task Force, which is reported in this article, is primarily a baseline for discussing novel future strategies for cardiovascular prevention. Also, this article is aimed at highlighting the importance of an emerging marker of cardiovascular risk, which is little recognized and often undervalued. Dysglycaemia, in turn, has a clinical significance, which is at least, in part, comparable with that of type 2 diabetes mellitus, both in terms of epidemiological prevalence and of long-term cardiovascular prognosis.",
keywords = "abnormal glucose regulation, cardiovascular prevention, diabetes mellitus, hypertension, impaired glucose tolerance, insulin resistance, metabolic syndrome",
author = "Massimo Volpe and Claudio Borghi and {Cavallo Perin}, Paolo and Massimo Chiariello and Enzo Manzato and Roberto Miccoli and Modena, {Maria Grazia} and Gabriele Riccardi and Giorgio Sesti and Antonio Tiengo and Bruno Trimarco and Diego Vanuzzo and Paolo Verdecchia and Augusto Zaninelli and {Del Prato}, Stefano",
year = "2010",
doi = "10.2165/11311830-000000000-00000",
language = "English",
volume = "17",
pages = "73--102",
journal = "High Blood Pressure and Cardiovascular Prevention",
issn = "1120-9879",
publisher = "Adis International Ltd",
number = "2",

}

TY - JOUR

T1 - Cardiovascular prevention in subjects with impaired fasting glucose or impaired glucose tolerance

AU - Volpe, Massimo

AU - Borghi, Claudio

AU - Cavallo Perin, Paolo

AU - Chiariello, Massimo

AU - Manzato, Enzo

AU - Miccoli, Roberto

AU - Modena, Maria Grazia

AU - Riccardi, Gabriele

AU - Sesti, Giorgio

AU - Tiengo, Antonio

AU - Trimarco, Bruno

AU - Vanuzzo, Diego

AU - Verdecchia, Paolo

AU - Zaninelli, Augusto

AU - Del Prato, Stefano

PY - 2010

Y1 - 2010

N2 - Cardiovascular diseases still represent the leading cause of mortality and hospitalization, particularly in Western countries. As a consequence of the marked changes observed on the demographic characteristics of the general population, the improved survival rate after an acute cardiovascular event, and the progressive rise of costs (mostly due to technological and pharmacological innovations), the estimated burden of cardiovascular diseases will soon become insurmountable for national healthcare systems. In this view, an integrated approach aimed at improving strategies for cardiovascular disease prevention and, thus, limiting the negative outcomes, would probably be successful. Such an approach may not only achieve long-term benefits, but even significant advantages in the short to medium term, mostly in asymptomatic high-risk individuals. Indeed, this latter population of asymptomatic high-risk individuals would mostly benefit from extensive application and improvement of strategies for cardiovascular disease prevention with a favourable cost-benefit ratio.The Italian Society for Cardiovascular Disease Prevention Societ Italiana per la Prevenzione Cardiovascolare (SIPREC) has recognized this strategic aim, focusing a vast majority of its institutional action on the effort for providing educational supports and consensus documents, which represent an overview of the scientific knowledge and personal clinical expertise by national and international key opinion leaders. Expert committees periodically generate 'state-of-the-art' documents on specific scientific topics with relevant socioeconomic implications and large clinical impact. The present article is dedicated to healthcare professionals, and is based on the available evidence, and provides useful information on diagnostic algorithms and therapeutic options. In 2006, the SIPREC Scientific Committee promoted a consensus document on the metabolic syndrome,1 which is still widely used, frequently cited and updated, from which originated a broad educational programme throughout the Italian territory. This programme has certainly contributed to improving knowledge of a widespread clinical condition, such as the metabolic syndrome, which SIPREC interpreted not only as a theoretical pathophysiological concept or a nosographic entity, but rather as a real clinical tool for identifying and 'intercepting' those asymptomatic individuals at risk of cardiovascular events, before the estimated level of risk becomes high.This new article may be viewed in the same strategic line. The relationship between abnormalities in blood glucose metabolism (or dysglycaemia) and cardiovascular complications represents another important and relatively early target for cardiovascular disease prevention. SIPREC Scientific Committee identified even in this clinical setting an excellent group of scientific experts, in order to collect a ultidisciplinary 'task force'. This group has been asked to explain in a short, simple and effective fashion the epidemiological impact and the pathophysiological nature of the problem, its clinical features, potential diagnostic algorithms and therapeutic options, and its influence on the clinical practice of both specialist physicians and general practitioners.The work of this Task Force, which is reported in this article, is primarily a baseline for discussing novel future strategies for cardiovascular prevention. Also, this article is aimed at highlighting the importance of an emerging marker of cardiovascular risk, which is little recognized and often undervalued. Dysglycaemia, in turn, has a clinical significance, which is at least, in part, comparable with that of type 2 diabetes mellitus, both in terms of epidemiological prevalence and of long-term cardiovascular prognosis.

AB - Cardiovascular diseases still represent the leading cause of mortality and hospitalization, particularly in Western countries. As a consequence of the marked changes observed on the demographic characteristics of the general population, the improved survival rate after an acute cardiovascular event, and the progressive rise of costs (mostly due to technological and pharmacological innovations), the estimated burden of cardiovascular diseases will soon become insurmountable for national healthcare systems. In this view, an integrated approach aimed at improving strategies for cardiovascular disease prevention and, thus, limiting the negative outcomes, would probably be successful. Such an approach may not only achieve long-term benefits, but even significant advantages in the short to medium term, mostly in asymptomatic high-risk individuals. Indeed, this latter population of asymptomatic high-risk individuals would mostly benefit from extensive application and improvement of strategies for cardiovascular disease prevention with a favourable cost-benefit ratio.The Italian Society for Cardiovascular Disease Prevention Societ Italiana per la Prevenzione Cardiovascolare (SIPREC) has recognized this strategic aim, focusing a vast majority of its institutional action on the effort for providing educational supports and consensus documents, which represent an overview of the scientific knowledge and personal clinical expertise by national and international key opinion leaders. Expert committees periodically generate 'state-of-the-art' documents on specific scientific topics with relevant socioeconomic implications and large clinical impact. The present article is dedicated to healthcare professionals, and is based on the available evidence, and provides useful information on diagnostic algorithms and therapeutic options. In 2006, the SIPREC Scientific Committee promoted a consensus document on the metabolic syndrome,1 which is still widely used, frequently cited and updated, from which originated a broad educational programme throughout the Italian territory. This programme has certainly contributed to improving knowledge of a widespread clinical condition, such as the metabolic syndrome, which SIPREC interpreted not only as a theoretical pathophysiological concept or a nosographic entity, but rather as a real clinical tool for identifying and 'intercepting' those asymptomatic individuals at risk of cardiovascular events, before the estimated level of risk becomes high.This new article may be viewed in the same strategic line. The relationship between abnormalities in blood glucose metabolism (or dysglycaemia) and cardiovascular complications represents another important and relatively early target for cardiovascular disease prevention. SIPREC Scientific Committee identified even in this clinical setting an excellent group of scientific experts, in order to collect a ultidisciplinary 'task force'. This group has been asked to explain in a short, simple and effective fashion the epidemiological impact and the pathophysiological nature of the problem, its clinical features, potential diagnostic algorithms and therapeutic options, and its influence on the clinical practice of both specialist physicians and general practitioners.The work of this Task Force, which is reported in this article, is primarily a baseline for discussing novel future strategies for cardiovascular prevention. Also, this article is aimed at highlighting the importance of an emerging marker of cardiovascular risk, which is little recognized and often undervalued. Dysglycaemia, in turn, has a clinical significance, which is at least, in part, comparable with that of type 2 diabetes mellitus, both in terms of epidemiological prevalence and of long-term cardiovascular prognosis.

KW - abnormal glucose regulation

KW - cardiovascular prevention

KW - diabetes mellitus

KW - hypertension

KW - impaired glucose tolerance

KW - insulin resistance

KW - metabolic syndrome

UR - http://www.scopus.com/inward/record.url?scp=77955433121&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955433121&partnerID=8YFLogxK

U2 - 10.2165/11311830-000000000-00000

DO - 10.2165/11311830-000000000-00000

M3 - Article

AN - SCOPUS:77955433121

VL - 17

SP - 73

EP - 102

JO - High Blood Pressure and Cardiovascular Prevention

JF - High Blood Pressure and Cardiovascular Prevention

SN - 1120-9879

IS - 2

ER -